AGIOS PHARMACEUTICALS, INC.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
AGIO$29.41+4.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · •Operating Model Update –
Operating Model Update –
o Over the course of 2026, Agios reviewed its operating model, and will have reduced its R&D headcount by over 100 roles by year-end, representing a more than 35% decrease compared with 2025. The company expects the associated cost savings of these reductions to be realized in 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.